Madhavbaug, a leading name in Ayurvedic healthcare and wellness, has officially announced its participation in the upcoming Bharat Connect Conference 2025, scheduled for 27th March 2025 at 2 PM. The conference, organized by Arihant Capital, is designed to provide a platform for emerging businesses to connect with investors and analysts, discussing market opportunities and business growth strategies.

The company, Vaidya Sane Ayurved Laboratories Limited, which operates under the Madhavbaug brand, has confirmed that its management team will participate virtually in the event. This aligns with the company’s commitment to engage with investors and analysts, ensuring transparency and fostering investor confidence.

As per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Madhavbaug has disclosed this participation under Regulation 30(6), read with Part A of Schedule III. The company assures that all discussions during the event will be based on publicly available information and will not involve any unpublished price-sensitive information (UPSI). This disclosure aligns with Madhavbaug’s Code of Practices and Procedures for Fair Disclosure of UPSI, ensuring ethical and regulatory compliance.

Key Highlights of the Participation

• Event Name: Bharat Connect Conference 2025
• Date & Time: 27th March 2025, 2 PM
• Mode of Participation: Virtual
• Organized By: Arihant Capital
• Objective: Interaction with investors and analysts to discuss business developments

This participation signifies Madhavbaug’s strategic intent to maintain strong relations with institutional investors, retail investors, and market analysts. Investor conferences like Bharat Connect Conference 2025 serve as crucial platforms where companies provide insights into their growth trajectory, financial performance, and future strategies.

Madhavbaug is a reputed company specializing in Ayurvedic healthcare solutions, with a focus on cardiac health, diabetes management, and holistic wellness treatments. Over the years, it has built a strong presence in the alternative medicine sector, integrating modern diagnostic techniques with traditional Ayurvedic therapies. The company has also made significant strides in franchise expansion, research, and patient care innovation.

Compliance with SEBI Regulations

In accordance with Regulation 46(2) of the SEBI Listing Regulations, Madhavbaug has also ensured that this information is made available on its official website (www.madhavbaug.org). This step demonstrates the company’s commitment to transparency, allowing shareholders and stakeholders to stay informed about its latest business engagements.

By participating in the Bharat Connect Conference 2025, Madhavbaug aims to highlight its financial performance, business roadmap, and key growth initiatives. The company is expected to discuss expansion plans, market trends, and investor expectations, further strengthening its position in the Ayurvedic healthcare sector.

Investors and analysts who follow Madhavbaug closely will find this participation valuable for assessing the company’s growth prospects. As the healthcare industry continues to evolve, Madhavbaug’s innovative approach to combining Ayurveda with modern medical practices remains a key driver of its business success.

The upcoming event will be a significant milestone for Madhavbaug, reinforcing its market presence while fostering strong investor relations. Investors are encouraged to stay updated with further disclosures and announcements from the company through official communication channels and regulatory filings.

The Upcoming IPOs in this week and coming weeks are  NAPS Global.

The Current active IPO are Balaji Phosphates, Shreenath Paper.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Update.